Increasing Awareness Regarding Cancer is Driving Indian Cancer Monoclonal Antibodies Market

Indian cancer monoclonal antibodies market is estimated to grow at a CAGR of 12.5% during the forecast period. Rising awareness regarding cancer is primarily encouraging market growth. Indian government programs to raise public awareness regarding cancer have been witnessed which is offering an opportunity for market growth. Cancer Awareness Campaign 2019 aims to create awareness regarding cancer amongst the Indian population. This intends to increase awareness regarding the importance of screening for early detection. The campaign named Raho cancer se do kadam aage, an initiative by the Indian Cancer Society. Additionally, the availability of some major entities providing affordable cancer treatment is further accelerating the demand for potential cancer therapies in the country. 

Browse the full report description of "Indian cancer monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Type (Naked, Conjugated, and Others), By Application (Breast Cancer, Liver Cancer, Blood Cancer, Brain Cancer, Colorectal Cancer, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/indian-cancer-monoclonal-antibodies-market

This includes Tata Memorial Hospital, Sri Shankara Cancer Hospital and Research Centre, Dharamshila Hospital and Research Centre (DHRC), and ICS Cancer Detection Centre, Mumbai. This, in turn, is driving the demand for monoclonal antibodies that serve as one of the established therapeutic strategies for both solid tumors and hematologic malignancies. It is a type of immunotherapy that stimulates the immune system of cancer patients and works to find and attack cancer cells. Increasing launches of cancer monoclonal antibody biosimilars are also providing scope for an increased access to cancer treatment in the country.

Scope of the Indian Cancer Monoclonal Antibodies Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Type and Application
• Competitive Landscape- AstraZeneca plc, Biocon Ltd., F. Hoffman-La Roche AG, Cadila Pharmaceuticals Ltd., and Dr. Reddy’s Laboratories, Inc.

Recent Strategic Initiatives in the Indian Cancer Monoclonal Antibodies Market

• In July 2020, Ahmedabad-based Cadila Pharmaceuticals Ltd. declared the introduction of biosimilar Rituximab in India. It is indicated for the treatment of rheumatoid arthritis and blood cancer launched within the brand name Ritucad. It is used to treat Non-Hodgkin’s lymphoma (a type of blood-related cancer). According to the company, over 28,000 new cases of Lymphoma are reported each year in India. This launch will increase the accessibility of cancer treatment in the country. 
• In August 2019, Dr. Reddy's Laboratories declared the launch of Versavo (bevacizumab). It is a biosimilar of Roche's Avastin in India, which is intended to treat multiple kinds of cancers (cervical cancer, metastatic breast cancer, recurrent glioblastoma, metastatic renal cell carcinoma, metastatic colorectal cancer, epithelial ovarian, non-squamous non-small cell lung cancer, fallopian tube, and primary peritoneal cancer. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Indian Cancer Monoclonal Antibodies Market-Segmentation

By Type

• Naked 
• Conjugated
• Others (Bispecific)

By Application

• Breast Cancer
• Liver Cancer
• Blood Cancer
• Brain Cancer
• Colorectal Cancer
• Others

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/indian-cancer-monoclonal-antibodies-market